title: [Pulmonary hypertension: Possible genetic causes and therapeutic options].
abstract: Pulmonary hypertension (PH) is a severe disease, which is usually only recognized at a late stage. It is characterized by dyspnea and right heart insufficiency. In some forms of pulmonary hypertension, such as the rare pulmonary arterial hypertension (PAH) and PAH associated with congenital heart defects, genetic factors have been identified. This article summarizes the general and supportive therapies for PH, targeted pharmaceutical treatment for PAH and non-operable chronic thromboembolic pulmonary hypertension. To achieve acceptable survival rates, it is essential to transfer patients to an expert center at an early stage for further differential diagnostics and therapy.
authors.affiliation: Zentrum für Pulmonale Hypertonie, Thoraxklinik, Universitätsklinikum Heidelberg, Amalienstr. 5, 69126, Heidelberg, Deutschland, ekkehard.gruenig@med.uni-heidelberg.de.
authors.forename: E
authors.initials: E
authors.lastname: Grünig
authors.forename: C A
authors.initials: CA
authors.lastname: Eichstaedt
authors.forename: N
authors.initials: N
authors.lastname: Ehlken
authors.forename: E
authors.initials: E
authors.lastname: Mayer
authors.forename: H
authors.initials: H
authors.lastname: Klose
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005081:Exercise Therapy; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D000959:Antihypertensive Agents